June 25, 2020 / 5:20 AM / 12 days ago

BRIEF-Onxeo Confirms Preclinical Profile Of OX401

June 25 (Reuters) - ONXEO SA:

* ONXEO CONFIRMS IN PRECLINICAL STUDIES THE PROFILE OF OX401, A POTENT PARP AGONIST WITH STRONG ANTI-TUMOR ACTIVITY AND IMMUNOLOGICAL PROPERTIES

* PRECLINICAL PROGRAM ALREADY COMPLETED HAS CONFIRMED KEY PROPERTIES OF THIS NEW COMPOUND

* TRANSLATIONAL STUDIES WILL ALLOW TO BEST PREPARE FOR ENTRY INTO CLINIC, WHICH COULD TAKE PLACE WITHIN 18 TO 24 MONTHS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below